Johns Hopkins University, Baltimore, MD, United States of America.
University of Tennessee Health Science Center, Memphis, TN, United States of America.
PLoS One. 2019 Aug 8;14(8):e0219899. doi: 10.1371/journal.pone.0219899. eCollection 2019.
Although hypokalemia has been viewed as a significant concern among patients with heart failure (HF), recent advances in HF management tend to increase the risk of hyperkalemia.
To characterize contemporary data regarding correlates and prognostic values of dyskalemia in patients with HF.
DESIGN, SETTING, AND PARTICIPANTS: In cross-sectional and longitudinal analyses, we studied 142,087 patients with newly diagnosed HF in US nationwide Veterans Administration database from 2005 through 2013.
Demographic characteristics, laboratory variables, comorbidities, and medication use for the analysis of correlates of dyskalemia as well as potassium level in the analysis of mortality.
Dyskalemia and mortality.
Hypokalemia (<3.5 mmol/L) at baseline was observed in 3.0% of the population, whereas hyperkalemia (≥5.5 mmol/L) was seen in 0.9%. An additional 20.4% and 5.7% had mild hypokalemia (3.5-3.9 mmol/L) and mild hyperkalemia (5.0-5.4 mmol/L). Key correlates were black race, higher blood pressure, and use of potassium-wasting diuretics for hypokalemia, and lower kidney function for hyperkalemia. Baseline potassium levels showed a U-shaped association with mortality, with the lowest risk between 4.0-4.5 mmol/L. With respect to potassium levels over a year after HF diagnosis, persistent (>50% of measurements), intermittent (>1 occurrence but ≤50%), and transient (1 occurrence) hypo- and hyperkalemia were also related to increased mortality in a graded fashion regardless of the aforementioned thresholds for dyskalemia. These dyskalemic patterns were also related to other clinical actions and demands such as emergency room visit.
Potassium levels below 4 mmol/L and above 5 mmol/L at and after HF diagnosis were associated with poor prognosis and the clinical actions. HF patients (particularly with risk factors for dyskalemia like black race and kidney dysfunction) may require special attention for both hypo- and hyperkalemia.
虽然低钾血症一直被认为是心力衰竭(HF)患者的一个重要关注点,但 HF 治疗的最新进展往往会增加高钾血症的风险。
描述 HF 患者中电解质紊乱的相关性和预后价值的最新数据。
设计、地点和参与者:在横断面和纵向分析中,我们研究了 2005 年至 2013 年间美国退伍军人事务部全国数据库中 142087 例新诊断为 HF 的患者。
人口统计学特征、实验室变量、合并症和药物使用,用于分析电解质紊乱的相关性,以及钾水平用于分析死亡率。
电解质紊乱和死亡率。
基线时低血钾症(<3.5mmol/L)发生率为 3.0%,高血钾症(≥5.5mmol/L)发生率为 0.9%。另有 20.4%和 5.7%的患者存在轻度低血钾症(3.5-3.9mmol/L)和轻度高血钾症(5.0-5.4mmol/L)。主要相关因素是黑种人、更高的血压和使用排钾利尿剂治疗低血钾症,以及低肾功能与高钾血症相关。基线钾水平与死亡率呈 U 型关联,风险最低的钾水平在 4.0-4.5mmol/L 之间。就 HF 诊断后一年的钾水平而言,持续性(>50%的测量值)、间歇性(>1 次但≤50%)和短暂性(1 次)低血钾和高血钾呈分级趋势与死亡率增加相关,无论上述电解质紊乱的阈值如何。这些电解质紊乱模式也与其他临床操作和需求相关,如急诊就诊。
HF 诊断时和诊断后钾水平低于 4mmol/L 和高于 5mmol/L 与预后不良和临床操作相关。HF 患者(特别是具有低钾血症危险因素的患者,如黑种人和肾功能障碍)可能需要特别注意低钾血症和高钾血症。